Drug intelligence / Profile preview

NBI04

Development stage: Preclinical
Lead developer: Noile-Immune Biotech
Modality: CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
Administration: Intravenous

Overview

NBI04 is an investigational cancer immunotherapy being developed by Noile-Immune Biotech. It is a chimeric antigen receptor T-cell (CAR-T) therapy that utilizes the company's proprietary PRIME (Proliferation-inducing and migration-enhancing) technology. This platform involves engineering CAR-T cells to co-express Interleukin-7 (IL-7) and Chemokine (C-C motif) ligand 19 (CCL19), which are intended to improve the proliferation, survival, and infiltration of both the CAR-T cells and endogenous immune cells into solid tumors. As of early 2024, NBI04 is in the pre-clinical stage of development for the treatment of solid tumors, with its specific tumor-associated antigen target currently undisclosed.

Beyond the preview

Go deeper on NBI04.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NBI04.

Explore the full profile